Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Orion Signs License Agreement with Janssen | Contract Pharma

What are you searching for?

Sign in
Breaking News

Orion Signs License Agreement with Janssen

To develop and commercialize novel treatment for Alzheimer's disease

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Orion Corp. has entered into a license agreement with Janssen Pharmaceuticals for the development and commercialization of Orion’s investigational alpha-2c adrenoceptor antagonists for the symptoms of Alzheimer’s disease, including clinical phase compound ORM-12741.
 
Orion will receive an upfront payment of $31 million and is eligible to receive payments upon completion of certain development and commercialization milestones, as well as royalties on future sales. Orion will use the majority of the up-front payment for costs associated with an additional Phase IIa study.
 
Orion will have exclusive commercialization rights in Europe and will grant Janssen a worldwide license to develop ORM-12741 and other compounds from the alpha-2c platform. Janssen will have an exclusive right to commercialize these compounds outside Europe. Orion and Janssen will co-fund development the Phase IIa study is completed.
 
Dr. Reijo Salonen, senior vice president of R&D at Orion, said, “In our collaboration with Janssen, I believe we will have the best of all worlds. At Janssen, there is a track record of success and commitment of developing therapies in Neurosciences. At Orion, we have a track record of inventing innovative molecules; and for Alzheimer patients, we hope that this partnership will bring them a novel medicine that will make an important difference to their lives.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics